Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.

Shuji Nakamoto
Yusuke Kumamoto
Kazuharu Igarashi
Yoshiki Fujiyama
Nobuyuki Nishizawa
Shigenori Ei
Hiroshi Tajima
Takashi Kaizu
Masahiko Watanabe
Keishi Yamashita

Open link

Publication date

January 2018

DOI

10.1371/journal.pone.0205864

Publisher

Public Library of Science (PLoS)

Journal

PLoS ONE

Abstract

BACKGROUND:Promoter DNA methylation of Cysteine dioxygenase type1 (CDO1) gene has been clarified as a molecular diagnostic and prognostic indicator in various human cancers. The aim of this study is to investigate the clinical relevance of CDO1 methylation in primary biliary tract cancer (BTC). METHODS:CDO1 DNA methylation was assessed by quantitative methylation-specific PCR in 108 BTC tumor tissues and 101 corresponding normal tissues. BTC was composed of extrahepatic cholangiocarcinoma (EHCC) (n = 81) and ampullary carcinoma (AC) (n = 27). RESULTS:The CDO1 methylation value in the tumor tissues was significantly higher than that in the corresponding normal tissues (p<0.0001). The overall survival (OS) in EHCC patients with hypermethylati...